hair loss while on glp 1 GLP-1 Loss: Causes and Treatments GLP-1 Hair Loss: Ozempic Shedding

In the key Phase 3 ATTAIN-1 trial published in the New England Journal of Medicine in 2025, once-daily orforglipron 36 mg produced mean body weight reductions of 11.2% at 72 weeks in adults with obesity, with nearly 55% of participants achieving at least 10% weight loss and 36% achieving 15% or more

NSAIDs can cause toxicity in the gastrointestinal tract, kidneys, and cardiovascular system

Both are weekly subcutaneous injections using a pre-filled pensimilar to insulin pens

NR's role in boosting NAD+ for longevity NR has emerged as a powerful NAD+ precursor that could slow aging

NOT FOR HUMAN USAGE

While it doesnt provide whole-genome insights, it can still help individuals understand hereditary conditions